期刊文献+

保定市2010年麻疹减毒活疫苗强化免疫疑似预防接种异常反应分析 被引量:1

Analysis on adverse events following immunization of measles attenuated live vaccine after supplementary immunization activities in Baoding in 2010
原文传递
导出
摘要 目的分析麻疹减毒活疫苗(measles attenuated live vaccine,MV)强化免疫活动(supplementary immunizationactivities,SIA)疑似预防接种异常反应(adverse events following immunization,AEFI)发生情况。方法对保定市2010年的MV,SIA,AEFI开展监测和分析。结果全市共报告AEFI 157例,报告发生率8.28/10万剂;男性多于女性,发生率随年龄增加逐渐降低;一般反应报告发生率4.91/10万剂;异常反应报告发生率2.90/10万剂,以过敏性皮疹为主(1.69/10万剂),其次为过敏性紫癜(0.90/10万剂);64.84%发生在接种后≤1d。结论 MV的安全性良好,接种MV后<1d是监测的重点。 Objective To analyze the adverse event following immunization (AEFI) of measles attenuated live vaccine (MV) after supplementary immunization activity (SIA) . Method Monitor and analyze the data of AEFI in Baoding in 2010. Results 157 cases of AEFI were reported, and the incidence was 8.28/100 000. Male cases were larger than female ones. The incidence reduced along with age. The incidence rates of common event and adverse event were 4. 91/100 000 and 2.90/100 000. Most adverse cases were anaphylactic rash ( 1.69/100 000 ) , followed by anaphylactoid purpura ( 0. 90/100 000 ) . 64. 84% of cases occurred within 1 days after immunization. Conclusions MV has good safety, and people should be observed within 1 day after vaccination.
出处 《医学动物防制》 2013年第4期448-450,共3页 Journal of Medical Pest Control
关键词 麻疹减毒活疫苗 强化免疫 疑似预防接种异常反应 Measles attenuated live vaccine Supplementary immunization Adverse events following immunization
  • 相关文献

参考文献9

二级参考文献30

  • 1郭飚,曹雷,曹玲生,徐立君,梁晓峰,张振国,罗耀星,孙印旗,彭国文,赵占杰.河北、广东省预防接种副反应监测试点培训效果评估[J].中国计划免疫,2005,11(4):302-305. 被引量:34
  • 2庄菱,郭飚,刘大卫,曹玲生,曹雷.全国预防接种异常反应监测省级师资培训效果评估[J].中国计划免疫,2006,12(3):218-220. 被引量:9
  • 3王宏东,赵瑛国,马小娜.儿童过敏性紫癜84例临床分析[J].中国皮肤性病学杂志,2007,21(3):159-160. 被引量:1
  • 4张永基,张守荣,胡苑笙,阿克忠,赵建海,余文周,左树岩,Yoshihiro Takashima,石西安.青海省2006年麻疹减毒活疫苗强化免疫效果评价[J].中国计划免疫,2007,13(3):257-260. 被引量:10
  • 5WHO/Immunization Vaccines and Biologicals(IVB). Joint Medical Products Assessment Tools of National Regulatory System Vaccines Assessment[S]. Geneva, Switzerland, 2004.
  • 6WHO&WPRO. Immunization safety surveillance:guidelines for managers of immunization programmes on reporting and investigating adverse events following immunization[S]. Manila, Philiodines. 1999.
  • 7Tarvin SE, Ballinger S. Henoch-Schonlein purpura[J]. Current Paediatrics, 2006, 16: 259-263.
  • 8Gardner-Medwin JMM, Dolezalova P, Cummins C, et al. Incidence of Henoch-SchSnlein purpura; Kawasaki disease, and rare vasculitides in children of different ethnic origins[J]. Lancet, 2002, 360: 1197-1202.
  • 9Pless RP, Bentsi-Enchill AD, Duclos P, et al. Monitoring Vaccine Safety during Measles Mass Immunization Campaigns: Clinical and Programmatic Issues [J]. The Journal of Infectious Diseases, 2003, 187(Suppl1): S291-298.
  • 10Weigong Z, Vitali P, John KI, et al, Surveillance for Safety After Immunization: Vaccine Adverse Event Reporting System (VAERS) --United States, 1991-9001 [J]. MMWR, 2003,52(No. SS-1):1-24.

共引文献230

同被引文献13

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部